UBS Group
IRMD icon

UBS Group’s iRadimed IRMD Stock Holding History

UBS Group’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.41M Sell
14,642
-2,326
-14% -$233K ﹤0.01% 5273
2025
Q4 		$1.65M Sell
16,968
-8,465
-33% -$726K ﹤0.01% 5137
2025
Q3 		$1.81M Buy
25,433
+20,242
+390% +$1.35M ﹤0.01% 5051
2025
Q2 		$310K Sell
5,191
-3,921
-43% -$215K ﹤0.01% 6410
2025
Q1 		$478K Sell
9,112
-10,688
-54% -$600K ﹤0.01% 5884
2024
Q4 		$1.09M Buy
19,800
+13,812
+231% +$727K ﹤0.01% 5236
2024
Q3 		$301K Buy
5,988
+1,260
+27% +$58.1K ﹤0.01% 5567
2024
Q2 		$208K Sell
4,728
-3,747
-44% -$159K ﹤0.01% 5637
2024
Q1 		$373K Buy
8,475
+1,237
+17% +$54.7K ﹤0.01% 5418
2023
Q4 		$344K Buy
7,238
+4,349
+151% +$183K ﹤0.01% 5401
2023
Q3 		$128K Sell
2,889
-12,149
-81% -$564K ﹤0.01% 5671
2023
Q2 		$718K Buy
15,038
+7,370
+96% +$332K ﹤0.01% 4520
2023
Q1 		$302K Sell
7,668
-2,248
-23% -$81.7K ﹤0.01% 5082
2022
Q4 		$281K Buy
9,916
+9,125
+1,154% +$261K ﹤0.01% 5184
2022
Q3 		$24K Sell
791
-602
-43% -$21K ﹤0.01% 7146
2022
Q2 		$47K Sell
1,393
-1,229
-47% -$44.1K ﹤0.01% 5964
2022
Q1 		$117K Buy
2,622
+174
+7% +$8.05K ﹤0.01% 5788
2021
Q4 		$113K Buy
+2,448
New +$98.8K ﹤0.01% 6200
2021
Q3 		– Sell
-3
Closed – – 9794
2021
Q2 		$0 Sell
3
-1,677
-100% -$46.2K ﹤0.01% 9579
2021
Q1 		$43K Buy
1,680
+536
+47% +$12.8K ﹤0.01% 6700
2020
Q4 		$26K Sell
1,144
-212
-16% -$4.9K ﹤0.01% 6750
2020
Q3 		$29K Sell
1,356
-1,184
-47% -$26.6K ﹤0.01% 6018
2020
Q2 		$59K Sell
2,540
-2,104
-45% -$45.2K ﹤0.01% 5721
2020
Q1 		$99K Sell
4,644
-1,640
-26% -$39.1K ﹤0.01% 5303
2019
Q4 		$147K Buy
6,284
+1,427
+29% +$33.3K ﹤0.01% 5794
2019
Q3 		$102K Buy
4,857
+606
+14% +$12.4K ﹤0.01% 5758
2019
Q2 		$87K Buy
4,251
+2,735
+180% +$64.4K ﹤0.01% 5471
2019
Q1 		$43K Sell
1,516
-39
-3% -$1.02K ﹤0.01% 5666
2018
Q4 		$38K Sell
1,555
-313
-17% -$8.41K ﹤0.01% 6317
2018
Q3 		$69K Sell
1,868
-157
-8% -$4.24K ﹤0.01% 5898
2018
Q2 		$42K Buy
2,025
+256
+14% +$4.53K ﹤0.01% 6123
2018
Q1 		$25K Buy
1,769
+28
+2% +$399 ﹤0.01% 6249
2017
Q4 		$26K Buy
+1,741
New +$22.1K ﹤0.01% 6351
2017
Q3 		– Sell
-4,130
Closed -$35K – 7854
2017
Q2 		$35K Buy
4,130
+2,564
+164% +$21.9K ﹤0.01% 5909
2017
Q1 		$14K Sell
1,566
-798
-34% -$7.4K ﹤0.01% 6405
2016
Q4 		$26K Buy
2,364
+323
+16% +$3.48K ﹤0.01% 6338
2016
Q3 		$35K Buy
2,041
+1,628
+394% +$30.1K ﹤0.01% 5803
2016
Q2 		$9K Buy
+413
New +$7.43K ﹤0.01% 6835
2016
Q1 		– Sell
-24,002
Closed -$673K – 7882
2015
Q4 		$673K Buy
+24,002
New +$679K ﹤0.01% 3718
2015
Q2 		– Sell
-1,013
Closed -$15K – 8665
2015
Q1 		$15K Buy
+1,013
New +$15K ﹤0.01% 7283

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group's IRMD Position: Q1 2026 in Review

UBS Group reduced its iRadimed (IRMD) stake by 14% in Q1 2026, selling an estimated $233K and leaving 14,642 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #5273.

UBS Group first reported a position in IRMD in Q1 2015 and has held it in 40 quarters since. The position peaked at $1.81M in Q3 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • UBS Group held 14,642 shares of iRadimed worth $1.41M as of Q1 2026.
  • UBS Group sold 2,326 iRadimed shares in Q1 2026, an estimated $233K.
  • iRadimed made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5273 holding.
  • UBS Group first reported a position in iRadimed in Q1 2015 and has held it in 40 quarters since.
  • UBS Group's iRadimed position peaked at $1.81M in Q3 2025.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.